Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== Central nervous system and appetite regulation ==== GLP-1 receptor activation stimulates satiety, thus reducing food intake, promoting the development of a negative energy balance, and decreasing body weight over time, making GLP-1 agonists a treatment option for obesity. In the hypothalamus, this is achieved by stimulating anorexigenic (satiety-inducing) POMC and CART neurons while simultaneously inhibiting orexigenic (appetite-inducing) AgRP and NPY neurons. GLP-1 agonists also counteract obesity-induced leptin resistance. They do this by downregulating inhibitory proteins like SOCS3 and PTP1B, which restores the brain's JAK/STAT signaling cascade and re-establishes sensitivity to leptin.
Tapentadol, sold under the brand names Nucynta and Palexia among others, is a synthetic opioid analgesic with a dual mode of action as a highly selective full agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Tapentadol is used medically for the treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. Frequently reported adverse effects include euphoria, constipation, nausea, vomiting, headaches, loss of appetite, drowsiness, dizziness, itching, dry mouth, and sweating. More severe adverse reactions can occur, including addiction and dependence, substance abuse, respiratory depression, and an elevated risk of serotonin syndrome. Concurrent use of tapendatol with serotonergic drugs can heighten the risk of excessive serotonin accumulation while concurrent use with CNS depressants — alcohol, benzodiazepines, other opioids — can heighten the risk of profound sedation, dangerously slowed breathing, and death. Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours. Tapentadol is taken by mouth, and is available in immediate-release and controlled-release formulations. Tapentadol's combined mechanism of action is often compared to that of tramadol. Unlike tramadol, tapentadol is not metabolised by cytochrome P450 enzymes, but rather through glucuronidation. Due to this, tapentadol has fewer interactions with other medications and fewer side effects when compared with tramadol. Like tramadol, tapentadol affects both the opioid system and the norepinephrine system to relieve pain.
=== Blocked catheters === Alteplase can be used in small doses to clear blood clots that obstruct a catheter, reopening the catheter so it can continue to be used. Catheter obstruction is commonly observed with a central venous catheter. Currently, the standard treatment for catheter obstructions in the United States is alteplase administration. Alteplase is effective and low risk for treating blocked catheters in adults and children. Overall, adverse effects of alteplase for clearing blood clots are rare. Novel alternatives to treat catheter occlusion, such as tenecteplase, reteplase, and recombinant urokinase, offer the advantage of shorter dwell times than alteplase.
Flavor ingredients used in instant ramen noodle soup include dried vegetables and meats, salt, MSG, onion, garlic, yeast extract, hydrolyzed vegetable protein, essential oil extracts and natural or synthetic flavor compounds. Essential oils derived from onion, garlic and clove are sometimes used as flavorings for instant ramen soup, and may be manufactured using expeller pressing or solvent extraction and distillation. Sophisticated methods exist that create flavor compounds, or complex flavors, for the flavoring of instant ramen noodle soups. A desired flavor is analyzed using techniques such as gas chromatography utilized with mass spectrometry and olfactometry, so that it can be reconstituted through blending more common ingredients.
Extreme UV (EUV or sometimes XUV) is characterized by a transition in the physics of interaction with matter. Wavelengths longer than about 30 nm interact mainly with the outer valence electrons of atoms, while wavelengths shorter than that interact mainly with inner-shell electrons and nuclei. The long end of the EUV spectrum is set by a prominent He+ spectral line at 30.4 nm. EUV is strongly absorbed by most known materials, but synthesizing multilayer optics that reflect up to about 50% of EUV radiation at normal incidence is possible. This technology was pioneered by the NIXT and MSSTA sounding rockets in the 1990s, and it has been used to make telescopes for solar imaging. See also the Extreme Ultraviolet Explorer satellite.
Sources: en.wikipedia.org
A typical teleost fish has a streamlined body for rapid swimming, and locomotion is generally provided by a lateral undulation of the hindmost part of the trunk and the tail, propelling the fish through the water. There are many exceptions to this method of locomotion, especially where speed is not the main objective; among rocks and on coral reefs, slow swimming with great manoeuvrability may be a desirable attribute. Eels locomote by wiggling their entire bodies. Living among seagrasses and algae, the seahorse adopts an upright posture and moves by fluttering its pectoral fins, and the closely related pipefish moves by rippling its elongated dorsal fin. Gobies "hop" along the substrate, propping themselves up and propelling themselves with their pectoral fins. Mudskippers move in much the same way on terrestrial ground. In some species, a pelvic sucker allows them to climb, and the Hawaiian freshwater goby climbs waterfalls while migrating. Gurnards have three pairs of free rays on their pectoral fins which have a sensory function but on which they can walk along the substrate. Flying fish launch themselves into the air and can glide on their enlarged pectoral fins for hundreds of metres.
Elizabeth Evans Hughes Gossett (August 19, 1907 – April 21, 1981), the daughter of statesman Charles Evans Hughes, was the first American, and one of the first people in the world, treated with insulin for type 1 diabetes. She received over 42,000 insulin shots over her lifetime.
Neohormones are a group of recently evolved hormones primarily associated to the success of mammalian development. These hormones are specific to mammals and are not found in other vertebrates—this is because neohormones are evolved to enhance specific mammalian functions. In males, neohormones play important roles in regulating testicular descent (the testes descend into the scrotum during foetal development) and preparing the sperm for internal fertilisation (the sperm fertilizes the egg within the female). In females, neohormones are essential for regulating early pregnancy, mammary gland development lactation (secretion of milk from the mammary gland), and viviparity (allowing the fertilized egg to grow inside the female until they can exist independently). Neohormones superimpose their actions on the hypothalamic-pituitary-gonadal axis (a hormone system which regulates key reproductive functions in animals) and are not associated with other core bodily functions.
The National Institute for Occupational Safety and Health (NIOSH) considers a drug to be hazardous if it exhibits one or more of the following characteristics in humans or animals: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing hazardous drugs. Specialty pharmacies that stock and dispense medications on the NIOSH list of Hazardous Drugs must follow strict standards. Community pharmacies typically handle some Hazardous Drugs; therefore, using pharmacy automation for Hazardous Drugs generally follows this guideline: pharmacy staff use an exception tray and spatula to count any Hazardous Drug, and decontaminate the tray and spatula immediately following. Pharmacy robots should not store any Hazardous Drugs for chance of pill-grinding and dust-generation. All other medications dispensed in the pharmacy that are not Hazardous Drugs can be counted with pharmacy automation safely if the manufacturer's cleaning directions are followed.
Because a commercial TOFMS uses a higher voltage pulsed extraction with longer flight tube with other optimized conditions, it generally has better sensitivity and resolution than a suitcase TOF. However, in the case of very high mass compounds, the suitcase TOF shows as good resolution and sensitivity as the commercial TOF. The suitcase TOF was also tested with a series of chemical weapons agents. Every compound tested was detected at levels comparable to standard analytical techniques for these agents.
Sources: en.wikipedia.org
== Medical uses == Posaconazole is used to treat invasive Aspergillus and Candida infections. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to other drugs such as itraconazole and fluconazole. Clinical evidence of efficacy in treatment of invasive disease caused by Fusarium species (fusariosis) is limited. Intravenous administration appears to be helpful in a mouse model of naegleriasis and the drug kills Acanthamoeba castellanii cysts in vitro. It has been used to treat mucormycosis (black fungus disease) caused by Rhizopus mold.
Today the Catholic devotions to the Holy Face of Jesus are usually associated with the negative image of the Shroud of Turin, as first captured in Secondo Pia's 1898 photograph. However, these devotions predate Pia's image, having been established in 1844 by the Carmelite nun Marie of St Peter, based on depictions of Jesus before his crucifixion and associated with the tradition of the Veil of Veronica. This devotion was then promoted by a French Catholic layman, Leo Dupont, who became known as the "Apostle of the Holy Face". In 1851 Dupont formed the "Archconfraternity of the Holy Face" in the city of Tours. Pope Leo XIII approved the devotion to the Holy Face in 1885. The popular French Saint Thérèse of Lisieux took the name "Thérèse of the Child Jesus and the Holy Face" when she became a Discalced Carmelite in 1889. Saint Thérèse, who died in 1897, also helped to spread the devotion to the Holy Face before it became associated with Pia's photographic image of the Shroud of Turin. The modern devotion to the Holy Face centered on the negative photographic image from the Shroud of Turin derives principally from an Italian nun born in Milan, Maria Pierina De Micheli, who reported having visions of Jesus starting in 1936. Sister Maria Pierina designed a "Holy Face Medal", based on Secondo Pia's photographs. This medal was eventually approved for private devotion by Pope Pius XII.
== Business model == Dutch Bros operates as a chain. The vast majority of its stores have no indoor seating and are walk-up or drive-thru stands. Each store sells hot and cold drinks, including non-coffee options (including tea, milkshakes, and sparkling sodas) and a selection of baked goods. The company started franchising in 1999. In 2008, Dutch Bros transitioned to an internal franchising model that required potential franchisees to have worked for the company for a minimum of three years. This resulted in a 97% continuity rate among franchises; between 2010 and 2015, only 3% of all Dutch Bros franchise locations closed. In 2017, Dutch Bros stopped franchising and started opening only company-owned stores. As of June 2021, franchisees were running 264 Dutch Bros stores and another 207 were fully company-owned. The company has a history of buying out franchisees that failed to meet the company's customer-service standards.
== Registration == The U.S. Centers for Disease Control and Prevention administers a regulatory framework for disinfectants and sterilants. To earn virucidal registration, extensive data on harder-to-kill viruses demonstrating long-lasting virucidal efficacy need to be provided.
=== Athlete biological passport === The athlete biological passport is a program that tracks the location of an athlete to combat doping in sports. This means that the athlete can be monitored and drug tested wherever they are and this data can be compared to the history of their doping test results. There is an ongoing discussion about how this measure can be seen as a violation of an individual's privacy.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.